NasdaqCM - Delayed Quote USD

Jaguar Health, Inc. (JAGX)

0.1800 +0.0100 (+5.88%)
At close: April 26 at 4:00 PM EDT
0.1822 +0.00 (+1.22%)
After hours: April 26 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
10,721.0000
11,956.0000
4,335.0000
9,385.0000
Cost of Revenue
1,845.0000
2,019.0000
2,333.0000
3,280.0000
Gross Profit
8,876.0000
9,937.0000
2,002.0000
6,105.0000
Operating Expense
41,896.0000
44,352.0000
41,076.0000
27,409.0000
Operating Income
-33,020.0000
-34,415.0000
-39,074.0000
-21,304.0000
Net Non Operating Interest Income Expense
-8,768.0000
-12,723.0000
-10,055.0000
-8,135.0000
Other Income Expense
964.0000
-1,257.0000
-3,471.0000
-4,370.0000
Pretax Income
-40,824.0000
-48,395.0000
-52,600.0000
-33,809.0000
Net Income Common Stockholders
-39,711.0000
-47,454.0000
-52,595.0000
-38,648.0000
Diluted NI Available to Com Stockholders
-39,711.0000
-47,454.0000
-52,595.0000
-38,648.0000
Basic EPS
-0.87
-35.28
-86.01
-225.00
Diluted EPS
-0.87
-35.28
-86.01
-225.00
Basic Average Shares
11,441.6640
1,345.1470
611.4390
171.7440
Diluted Average Shares
24,815.7670
1,345.1470
611.4390
171.7440
Total Operating Income as Reported
-33,020.0000
-34,415.0000
-40,708.0000
-26,647.0000
Rent Expense Supplemental
902.0000
629.0000
282.0000
690.0000
Total Expenses
43,741.0000
46,371.0000
43,409.0000
30,689.0000
Net Income from Continuing & Discontinued Operation
-39,711.0000
-47,454.0000
-52,595.0000
-33,809.0000
Normalized Income
-39,371.0000
-45,247.0000
-49,889.0000
-29,249.0000
Interest Expense
8,768.0000
12,723.0000
8,421.0000
2,792.0000
Net Interest Income
-8,768.0000
-12,723.0000
-10,055.0000
-8,135.0000
EBIT
-32,056.0000
-35,672.0000
-44,179.0000
-31,017.0000
EBITDA
-29,657.0000
-33,380.0000
-42,366.0000
-28,737.0000
Reconciled Cost of Revenue
1,845.0000
2,019.0000
2,333.0000
3,280.0000
Reconciled Depreciation
2,399.0000
2,292.0000
1,813.0000
2,280.0000
Net Income from Continuing Operation Net Minority Interest
-39,711.0000
-47,454.0000
-52,595.0000
-33,809.0000
Total Unusual Items Excluding Goodwill
-340.0000
-2,207.0000
-2,706.0000
-4,560.0000
Total Unusual Items
-340.0000
-2,207.0000
-2,706.0000
-4,560.0000
Normalized EBITDA
-29,317.0000
-31,173.0000
-39,660.0000
-24,177.0000
12/31/2020 - 5/12/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
MLEC Moolec Science SA
1.4500
+2.11%
 
PCSA Processa Pharmaceuticals, Inc.
2.1500
-11.52%
 
PALI Palisade Bio, Inc.
6.05
-2.89%
 
ABVC ABVC BioPharma, Inc.
1.4200
-10.69%
 
BPTH Bio-Path Holdings, Inc.
2.6800
+1.71%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
OCGN Ocugen, Inc.
1.2800
+8.47%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%